Table 3.
Frequency of HAART in PLWH.
| HAART | n | % |
|---|---|---|
| NRTIs | ||
| LAM + ZDV | 18 | 6.5 |
| 4dT + ddl | 2 | 0.7 |
| LAM + ABC | 1 | 0.4 |
| LAM + ZDV + ABC | 1 | 0.4 |
| ZDV + ddl | 1 | 0.4 |
| Subtotal | 23 | 9.3 |
| NRTIs + NNRTIs | ||
| LAM + ZDV + EFV | 97 | 39.4 |
| LAM + ABC + EFV | 23 | 9.3 |
| LAM + ZDV + NVP | 20 | 8.1 |
| LAM + EFV | 7 | 2.8 |
| LAM + 4dT + EFV | 4 | 1.6 |
| LAM + ddl + EFV | 1 | 0.4 |
| LAM + ABC + NVP | 1 | 0.4 |
| LAM + 4dT + NVP | 1 | 0.4 |
| ZDV + ABC + EFV | 1 | 0.4 |
| ABC + ddl + EFV | 1 | 0.4 |
| Subtotal | 156 | 63.4 |
| NRTI + PI | ||
| LAM + ZDV + LPV + RTV | 24 | 9.8 |
| ABC + ddl + LPV + RTV | 6 | 2.4 |
| LAM + ZDV + NFV | 5 | 2.0 |
| LAM + ABC + LPV + RTV | 3 | 1.2 |
| LAM + 4dT + NFV | 3 | 1.2 |
| LAM + 4dT + LPV + RTV | 3 | 1.2 |
| ABC + LPV + RTV | 2 | 0.8 |
| LAM + LPV + RTV | 2 | 0.8 |
| LAM + ZDV + RTV | 1 | 0.4 |
| LAM + ABC + RTV | 1 | 0.4 |
| LAM + NFV | 1 | 0.4 |
| ZDV + LPV | 1 | 0.4 |
| ZDV + ddl + LPV + RTV | 1 | 0.4 |
| ZDV + LPV + RTV | 1 | 0.4 |
| ABC + 4dT + LPV + RTV | 1 | 0.4 |
| 4dT + LPV + RTV | 1 | 0.4 |
| Subtotal | 56 | 22.8 |
| NRTI + NNRTI + PI | ||
| LAM + ZDV + ATZ | 4 | 1.6 |
| ABC + ddl + RTV + FSM | 2 | 0.8 |
| LAM + ABC + ATZ | 1 | 0.4 |
| LAM + ZDV + NFV | 1 | 0.4 |
| LAM + ZDV + NVP + NFV | 1 | 0.4 |
| LAM + ZDV + NVP + RTV + FSM | 1 | 0.4 |
| Subtotal | 10 | 4.1 |
| PI + II | ||
| LPV + RAL | 1 | 0.4 |
| Subtotal | 1 | 0.4 |
| Total | 246 | 100 |
HAART, highly active antiretroviral therapy; II, Integrase inhibitors; NRTI, Nucleos (t)ide reverse transcriptase inhibitors; NNRTI, Non nucleos(t)ides reverse transcriptase inhibitors; PI, Protease inhibitors; ABC, Abacavir; ATZ, Atazanavir; ddl, Didanosine; EFV, Efavirenz; FSM, Fosamprenavir; LAM, Lamivudine; LPV, Lopinavir; NVP, Nevirapine; NFV, Nelfinavir; RAL, Raltegravir; RTV, Ritonavir; ZDV, Zidovudine; 4dT, Stavudine.